JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The firm’s analysis suggests CagriSema is likely to deliver 25% weight loss ...

Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...

“Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN. “Patients who believe that they’re getting access to a safe ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and weight-loss markets. Hims & Hers anticipates selling a generic version of ...

Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per ...

even their letter O sometimes comes slashed in half. But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk…. a pharmaceutical firm with a market cap of a half ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations, said that its net profit in the third quarter hit 27.3 billion Danish kroner, just above an LSEG ...

Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide By Robin Foster HealthDay Reporter THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs ...